Search hospitals > Quebec > MONTREAL
Montreal Heart Institute
Claim this profileMONTREAL, Quebec H1T 1C8
Global Leader in Heart Failure
Global Leader in Atrial Fibrillation
Conducts research for Coronary Artery Disease
Conducts research for Myocardial Ischemia
Conducts research for Myocardial Infarction or Heart Attack
220 reported clinical trials
21 medical researchers
Summary
Montreal Heart Institute is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Heart Failure, Atrial Fibrillation, Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction or Heart Attack and other specialties. Montreal Heart Institute is involved with conducting 220 clinical trials across 225 conditions. There are 21 research doctors associated with this hospital, such as Anita Asgar, Reda Ibrahim, MD, lena Rivard, MD, MSc, and Philippe Demers.Top PIs
Anita AsgarMontreal Heart Institute2 years of reported clinical research
Studies Mitral Valve Regurgitation
Studies Mitral Regurgitation
11 reported clinical trials
15 drugs studied
Reda Ibrahim, MDInstitut de Cardiologie de Montreal (Montreal Heart Inst.)6 years of reported clinical research
Studies Stroke
Studies Aortic Valve Stenosis
8 reported clinical trials
17 drugs studied
lena Rivard, MD, MScMontreal Heart Institute5 years of reported clinical research
Studies Sarcoidosis
Studies Cardiac Sarcoidosis
6 reported clinical trials
11 drugs studied
Philippe DemersMontreal Heart Institute2 years of reported clinical research
Studies Bleeding
Studies Ascending Aortic Aneurysm
5 reported clinical trials
8 drugs studied
Clinical Trials running at Montreal Heart Institute
Heart Failure
Bleeding
Atrial Fibrillation
Stroke
Ascending Aortic Aneurysm
Type 2 Diabetes
Inflammation
Cardiovascular Disease
Coronary Artery Disease
Heart Disease
Heart Surgery
for Coronary Artery Disease
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Recruiting1 award N/A4 criteria
Multidisciplinary Screening
for Heart Failure
This trial uses a computer program to identify potential heart failure patients from medical records, followed by blood tests and AI heart imaging. It targets patients at risk of heart failure to catch the condition early. The process involves scanning records, testing blood for a specific marker, and using AI for detailed heart images if needed.
Recruiting1 award N/A11 criteria
Ziltivekimab
for Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Recruiting1 award Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Montreal Heart Institute?
Montreal Heart Institute is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Heart Failure, Atrial Fibrillation, Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction or Heart Attack and other specialties. Montreal Heart Institute is involved with conducting 220 clinical trials across 225 conditions. There are 21 research doctors associated with this hospital, such as Anita Asgar, Reda Ibrahim, MD, lena Rivard, MD, MSc, and Philippe Demers.